Pearls

Caring for medical marijuana patients who request controlled prescriptions

Dan H. Nguyen, MD, and Thida M. Thant, MD

Dr. Nguyen is Assistant Professor, Department of Psychiatry and Dr. Thant is Psychosomatic Medicine Fellow, University of Colorado School of Medicine, Aurora, Colorado.

Disclosures

The authors report no financial relationships with any company whose products are mentioned in the article or with manufacturers of competing products.

Discuss this article at www.facebook.com/ CurrentPsychiatry (K)

wenty-eight states and Washington, DC, have legalized marijuana for treating certain medical conditions, but the United States Drug Enforcement Administration (DEA) still classifies marijuana as a Schedule I drug "with no currently accepted medical use and a high potential for abuse."1 In certain states, clinicians can recommend, but not prescribe, medical marijuana. There is limited guidance in caring for patients who use medical marijuana and request or use DEA-controlled prescription medications, such as benzodiazepines, stimulants, and/or opiates. Physicians can take the following steps to ensure safe care for patients who use medical marijuana and request or take a DEA-controlled prescription medication:

1. Understand your patients' point of view. Talk with patients who use medical marijuana about the history, frequency, and method of use, and reasons for using medical marijuana. Assess for psychiatric illnesses and any past or active treatment with DEA-controlled prescription medications.

2. Perform screens. Screen for risk factors, past psychiatric history, and prior or current substance use disorders. Treat any existing substance use disorders as appropriate.

3. Provide education. Discuss the risks of marijuana use and its potential adverse effects on the patient's illness. Explain that marijuana is not currently an FDA-approved treatment and that there often are safer, efficacious alternatives.

4. Set clear boundaries. Be upfront about what is safe clinical practice or the usual standard of medical care and practice within the scope of state and federal laws. Document treatment agreements, utilize prescription drug monitoring programs, and use blood and/or urine toxicology screens as needed. Be aware that a routine drug screen can detect marijuana exposure but may vary in detecting the quantity or length of marijuana use.²

5. Try harm reduction. Any marijuana use, including use that falls short of a *Cannabis* use disorder, may adversely impact cognition, mood, and/or anxiety.³ Reducing use or abstaining from marijuana use for at least 4 weeks^{4,5} or reducing or discontinuing the DEA-controlled medication if a patient continues marijuana use are reasonable interventions to see if psychiatric symptoms improve or remit. Polypharmacy with marijuana may place a patient at risk for substance use disorders or additive adverse effects or can hinder the recovery process.

6. Consider alternatives. If a patient feels strongly about continuing medical marijuana use, and you feel that their marijuana

Every issue of CURRENT PSYCHIATRY has its 'Pearls' Yours could be found here.

Read the 'Pearls' guidelines for manuscript submission at **CurrentPsychiatry.com**, or request a copy from Assistant Editor Jason Orszt at jorszt@frontlinemedcom.com. Then, share with your peers a 'Pearl' of wisdom from your years of practice. use is not clinically harmful and that psychiatric symptoms require treatment, consider medications without a known potential for abuse (eg, antidepressants, buspirone, or hydroxyzine for anxiety; alpha-agonists or atomoxetine for attention-deficit/hyperactivity disorder, etc.). Start such medications at low dosages, titrate slowly, and monitor for benefits and adverse effects.

7. Continue the conversation. Maintain an open and nonjudgmental stance when discussing medical marijuana. Roll with resistance, and frame discussions toward a shared goal of improving the patient's mental health as safely as possible while using the best medical evidence available. **8. Offer additional support.** Refer patients any additional services as appropriate, which may include psychotherapy, a pain specialist, or a substance abuse specialist.

References

- United States Drug Enforcement Administration. Drug scheduling. https://www.dea.gov/druginfo/ds.shtml. Accessed June 22, 2017.
- Verstraete AG. Detection times of drugs of abuse in blood, urine, and oral fluid. Ther Drug Monit. 2004:26(2); 200-205.
- Volkow ND, Baler RD, Compton WM, et al. Adverse health effects of marijuana use. N Engl J Med. 2014:370(23); 2219-2227.
- Schuster RM, Fontaine M, Nip E, et al. Prolonged cannabis withdrawal in young adults with lifetime psychiatric illness [published online February 27, 2017]. Prev Med. pii: S0091-7435(17)30075-0.
- Bonnet U, Preuss UW. The cannabis withdrawal syndrome: current insights. Subst Abuse Rehabil. 2017;8:9-37.

Record treatment agreements, utilize prescription drug monitoring programs, and use blood or urine toxicology screens

Calling residents in psychiatry: Express yourself!

Share your vision and experiences by writing for "Residents' Voices" a section of CURRENT PSYCHIATRY reserved for you and your peers

CURRENT PSYCHIATRY Editor-in-Chief Dr. Henry A. Nasrallah said it well: "Psychiatric residency transforms you in subtle and overt ways, modulates your interaction with others, and humbles you to recognize the divinely complex nature of every patient's selfhood, life story, and inner workings."

The Editors of CURRENT PSYCHIATRY believe that you have a compelling story to tell about your patients, your residency, or your mentors and colleagues. Why not share that story, in a few hundred words, in "Residents' Voices," at CurrentPsychiatry.com?

Here's how: STE 1 STE 2 Urrent STE

STEP Contact Editor Jeff Bauer at jbauer@frontlinemedcom.com to obtain a guide for contributors and to discuss a topic or ask questions about manuscript preparation. Then, submit a descriptive query for the Editors' consideration.

Submit the manuscript to Dr. Nasrallah at henry.nasrallah@currentpsychiatry. com. You'll receive a prompt decision on acceptability.

Your published essay gets the attention of more than 40,000 psychiatrists and psychiatry residents in the United States. They'll enjoy hearing from you.